PTC THERAPEUTICS INC. news, videos and press releases - Page 5
For more news please use our advanced search feature.
PTC THERAPEUTICS INC. - More news...
PTC THERAPEUTICS INC. - More news...
- Newman Ferrara LLP Announces Corporate Governance Investigations of PTC Therapeutics (PTCT)
- PTC Therapeutics' 2022 STRIVE Awards Program Funds Initiatives Supporting the Duchenne Patient Community
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating PTC Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
- PTC Therapeutics Provides a Corporate Update and Reports Second Quarter Financial Results
- PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2022 Financial Results
- Upstaza™ Granted Marketing Authorization by European Commission as First Disease-Modifying Treatment for AADC Deficiency
- SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Is Investigating PTC Therapeutics, Inc. for Potential Breaches of Fiduciary Duty By Its Board of Directors
- Thinking about buying stock in Convey Health Solutions, Blacksky Technology, PTC Therapeutics, Applied UV, or StealthGas?
- PTC Therapeutics to Host Call to Review Topline Results from Study 041 for Translarna™ (ataluren) in Nonsense Mutation Duchenne Muscular Dystrophy
- INVESTIGATION REMINDER: The Schall Law Firm Encourages Investors in PTC Therapeutics, Inc. with Losses to Contact the Firm
- INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in PTC Therapeutics, Inc. with Losses to Contact the Firm
- Biotech Investment Veteran Alethia Young Joins PTC Therapeutics' Board of Directors
- PTC Therapeutics to Participate at William Blair 42nd Annual Growth Stock Conference
- Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study
- FDA Approves Label Extension for Evrysdi® for Infants with Spinal Muscular Atrophy Under 2 Months Old
- PTC Therapeutics Receives Positive CHMP Opinion for Upstaza™ for the Treatment of AADC Deficiency
- PTC Therapeutics Provides a Corporate Update and Reports First Quarter Financial Results
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- PTC Therapeutics to Host Conference Call to Discuss First Quarter 2022 Financial Results
- PTC Therapeutics Provides Update on EMA Regulatory Review Timeline For Its AADC Deficiency Gene Therapy Program
- PTC Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
- PTC Therapeutics Announces Initiation of PIVOT-HD Phase 2 Clinical Trial to Evaluate PTC518 in Patients with Huntington's Disease
- PTC Therapeutics to Present New Data at the 2022 Muscular Dystrophy Association Clinical & Scientific Conference
- PTC Therapeutics to Participate at Upcoming Investor Conferences
- PTC Therapeutics Provides a Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
- PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year-End 2021 Financial Results
- FDA Grants Evrysdi® Priority Review Based on Results From Treating Pre-Symptomatic Infants with Spinal Muscular Atrophy
- PTC Therapeutics Announces Launch of 8th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community
- PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
